3D Tissue Models
Drug Repositioning Summit
Hyatt Harborside
101 Harborside Drive
Boston, MA

Schedule of Presentations:

Monday, October 6, 2008
08:00:00 Registration
09:00:00 Chairperson’s Opening Remarks Thomas Barnes
09:10:00 Drug Repositioning: More Than One Way to Skin a Cat Art Pappas
09:40:00 Repositioning With a Twist: Establishing New Composition of Matter IP and Indications for a Marketed Drug Iain Dukes
10:10:00 Pfizer's Hunt for Repositioning Opportunities
10:40:00 Coffee Break, Poster & Exhibit Viewing
11:15:00 Trends and Challenges in Drug Repositioning Deals and Collaborations Richard B Smith
11:45:00 New Patents for Old Drugs? The Role of Label-Based Strategies Ned Israelsen
12:15:00 Luncheon Workshop (Sponsorship Available) or Lunch on Your Own
13:30:00 Chairperson’s Remarks Christopher Lipinski
13:35:00 Repurposing of Enbrel for Alzheimer’s Disease Keynote Presentation Edward Tobinick
14:15:00 From Repositioning Hypothesis Toward Reinitiation of Clinical Testing: The Case of GL1001 Stephen Donahue
14:45:00 Receptorome Screening: A Facile Approach to Target Discovery and Liability Assessment Vincent Setola
15:15:00 Repurposing and Repositioning in Drug Discovery Anthony Macherone
15:45:00 Refreshment Break, Poster and Exhibit Viewing
16:30:00 Imatinib (Gleevec) for the Treatment of Autoimmune Diseases William H Robinson
17:00:00 “EffiPRO” – An Efficient, Comprehensive Platform for Efficacy Profiling of Compounds and Genetic Target Validation David Grass
17:15:00 Networking Reception
18:15:00 Close of Day One
Tuesday, October 7, 2008
08:00:00 Recent 505(b)(2) Experiences with FDA Breakfast Workshop Kenneth V. Phelps
08:45:00 Break
08:55:00 Chairperson’s Remarks
09:00:00 The Indications Discovery Unit at Pfizer: First Year Check Up Keynote Presentation Donald E. Frail
09:45:00 The MLR-1023 Story: Reverse Drug Discovery The MLR-1023 Story: Reverse Drug Discovery Andrew G. Reaume
10:15:00 Coffee Break, Poster and Exhibit Viewing
10:45:00 Viagra Attenuates Doxorubicin-Induced Cardiomyopathy in Mice Rakesh C. Kukreja
11:15:00 Case Study of the Rational Design and Testing of VT-122, a Promising Phase 2 Product Candidate for Cancer Cachexia Newell F. Bascomb
11:45:00 There’s Still Low Hanging Fruit: Three Repositioned Drugs in Clinical Testing for Brain Injury Patients Neal Farber
12:15:00 Luncheon Workshop (Sponsorship Available) or Lunch on Your Own
13:30:00 Chairperson’s Remarks Stephen Donahue
13:35:00 From Asthma to Atherosclerosis – A Repositioning Case Study Tilmann Brotz
14:05:00 The Chemokine Receptor CXCR4 as a Therapeutic Target: The Discovery and Development of Plerixafor (AMD3100) Simon p Fricker
14:35:00 Refreshment Break, Poster and Exhibit Viewing
15:00:00 Repositioning Milnacipran for Fibromyalgia Srinivas G Rao
15:30:00 Foundation Driven Drug Discovery & Development for Huntington’s Disease
16:00:00 Close of Conference
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.